Pulse Biosciences, Inc.
PLSE
$17.19
$0.704.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 99.56% | 102.77% | 57.46% | 27.37% | 3.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.99% | 61.66% | 21.36% | 14.66% | 11.01% |
| Operating Income | -69.99% | -61.66% | -21.36% | -14.66% | -11.01% |
| Income Before Tax | -65.68% | -62.45% | -20.01% | -14.86% | -3.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.68% | -62.45% | -20.01% | -14.86% | -3.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.68% | -62.45% | -20.01% | -14.86% | -3.43% |
| EBIT | -69.99% | -61.66% | -21.36% | -14.66% | -11.01% |
| EBITDA | -72.17% | -63.33% | -21.98% | -15.14% | -11.40% |
| EPS Basic | -40.96% | -44.16% | -11.73% | 7.40% | 32.28% |
| Normalized Basic EPS | -41.03% | -44.06% | -11.80% | 7.44% | 32.30% |
| EPS Diluted | -40.96% | -44.16% | -11.73% | 7.40% | 32.28% |
| Normalized Diluted EPS | -41.03% | -44.06% | -11.80% | 7.44% | 32.30% |
| Average Basic Shares Outstanding | 17.51% | 12.71% | 7.39% | 24.07% | 52.78% |
| Average Diluted Shares Outstanding | 17.51% | 12.71% | 7.39% | 24.07% | 52.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |